April 22 (Reuters) - Regeneron Pharmaceuticals REGN.O said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.